Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink‐6 randomized clinical trial
Authors' conclusion
SGLT2 inhibition with empagliflozin for 6 months did not have a significant impact on LA volume and function in patients with T2DM and coronary artery disease.
Study context
- Population
- Patients with coronary artery disease and T2D
- Participants
- 90 patients
- Comparison
- Empagliflozin vs placebo
- Empagliflozinn = 44
- Placebon = 46reference
- Primary endpoint
- Change in LA volume (cardiac magnetic resonance (CMR))
- Follow-up
- 6 months
Methodological detailsplacebo-controlled, blinded reader
- Placebo-controlled
- Blinded reader
Primary result
As reported in the abstract
Change in LA volume
Empagliflozin vs PlaceboAdjusted difference, mL/m2 (95% CI)P value
Indexed maximum LA volume
0.99(−1.7 to 3.7)
P = 0.47Indexed minimum LA volume
0.87(−0.9 to 2.6)
P = 0.32Further findings
| Outcome | Adjusted mean difference (95% CI) | P value | |
|---|---|---|---|
| Change in total LA emptying fraction · 6 months | - 0.01 (−0.05 to 0.03) | P = 0.59 | |
| −0.06−0.04−0.0200.020.04Difference (linear scale) |
Indexed maximum LA volume at baseline
Indexed minimum LA volume at baseline
Change in total left atrial (LA) emptying fraction · 6 months
- Similar between groups
Indexed maximum LA volume at baseline
- No significant difference at baseline
Original publication
Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink‐6 randomized clinical trial. Cardiovasc Diabetol. Published 28 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →